EN DE
Watch Corvus Pharmaceuticals Inc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Corvus Pharmaceuticals Inc (CRVS) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of Corvus Pharmaceuticals Inc stock $7.94, price $11.37, that is 30.2% below the price, quality 57 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US

CP Corvus Pharmaceuticals Inc logo Thin data Nov 11, 2026

Corvus Pharmaceuticals Inc

CRVS · US
Solid, but expensive

Our calculation puts a fair price 30% below what the stock costs today.

Quality 57/100
Mixed vs. peers (4/7)
Insiders bought $333,654 (6M)
Fair value $7.94 · Overvalued
Negative free cash flow
Narrow moat 9/100
Thin data
Estimate
Watch Corvus Pharmaceuticals Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$25.52 $0.6481 Fair Value $7.94 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 11, 2026.

How to read this chart

60‑month range $0.6481 – $25.52 · fair‑value band $5.95 – $9.92 · the $11.37 price screens above the $7.94 fair value. As of Nov 11, 2026.

Follow Corvus Pharmaceuticals in your weekly email

Every Wednesday you see whether Corvus Pharmaceuticals is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of product candidates that precisely target proteins that are critical to immune cell maturation and function in the United States.

Show moreShow less

The company's lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1b/2 clinical trial for the treatment of peripheral T cell lymphoma, atopic dermatitis, hidradenitis suppurativa, autoimmune lymphoproliferative syndrome, and solid tumors monotherapy, and asthma, diseases.

It also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of first line renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1 clinical trial for the treatment of non-small cell lung cancer.

It has a license agreement with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as license agreement with Scripps for the development and commercialization of mupadolimab.

Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in South San Francisco, California.

Stock analysis

Corvus Pharmaceuticals Inc (CRVS) currently trades at $11.37, while our estimate is $7.94, 30% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: $5.95 (bear) to $9.92 (bull), the price of $11.37 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 57/100 (solid quality), in the Healthcare sector.

Corvus Pharmaceuticals Inc reported revenue of $0 in FY2025 versus $0 in FY2021. Reported net income was −$15.3M in FY2025.

Key figures

Market cap $1.1B Small · EPS (TTM) $−0.7200 · Return on equity −45.9% · Return on assets (EBIT) −47.0% (5-year average) · Free cash flow −$33.0M · Net cash $3.6M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 9 out of 100 (medium confidence).

What moves the price

The share trades about 55% below its 52-week high and 75% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −30%, CRVS screens richer than that median.

Fair Value

Bear $5.95 Fair Value $7.94 Bull $9.92
Price $11.37 · Downside -30.2%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 57/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 75
Are margins and returns getting better?
Cashflow 100
Do the profits arrive as real cash?
Financial strength 80
Debt, balance sheet and risk of trouble
Investment 89
Does it invest with discipline instead of growing at any price?
Low Volatility 11
How calm the share price moves, does not count
Price momentum 32
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 57
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, 2 officers or directors bought shares worth $333,654, most recently on Jun 11, 2026. Buying cluster

  • BuyDavid Scott MooreDirector21,700 shares at $11.53$250,201Jun 11, 2026
  • BuyRichard A Miller MdPresident and CEO, Director6,932 shares at $12.04$83,453May 18, 2026

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 10, 2026. All filings at the SEC ↗

Revenue & earnings trend

What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

CRVS screens overvalued: fair value 30% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare Corvus Pharmaceuticals Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 849 stocks

Beats the industry median on 4/6 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 57 · Top 25%
Fair Value upside −30.2% · Below median
Profitability
Return on assets −21.5% · Above median
Operating margin (12 months) 0.0% · Above median
Growth and dividend
Revenue growth (quarter YoY) 0.0% · Above median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 17.16× · Priciest 25%

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $916.06 $1,275 +39% vs CRVS
Samsung Biologics Co 207940 1,468,000 KRW 1,661,000 KRW +13% vs CRVS
Vertex Pharmaceuticals Incorporated VRTX $547.89 $601.80 +10% vs CRVS
Genmab A/S GMAB kr 3,581 kr 3,880 +8% vs CRVS
argenx SE ARGX $971.55 $908.40 −7% vs CRVS
CSL Limited CSL A$201.68 A$181.40 −10% vs CRVS
Moderna, Inc MRNA $250.83 $158.70 −37% vs CRVS
BeOne Medicines AG 6160 HK$252.20 HK$152.80 −39% vs CRVS
Celltrion, Inc 068270 203,000 KRW 74,945 KRW −63% vs CRVS
Royalty Pharma plc RPRX $69.45 $19.01 −73% vs CRVS

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Corvus Pharmaceuticals Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Corvus Pharmaceuticals Inc Fair Value". https://www.fairvalue-calculator.com/stock/CRVS

Frequently asked questions

Is Corvus Pharmaceuticals Inc (CRVS) overvalued or undervalued?
As of Nov 11, 2026, our estimate of fair value is $7.94 versus a price of $11.37, about 30% lower (overvalued).
What is the fair value of CRVS?
Our estimate for Corvus Pharmaceuticals Inc is $7.94 (as of Nov 11, 2026), built from audited fundamentals. The current price: $11.37.
What is the quality score of CRVS?
Corvus Pharmaceuticals Inc has a Quality Score of 57/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Corvus Pharmaceuticals Inc (CRVS)?
Our calculated price target is the estimate of $7.94 (as of Nov 11, 2026). Cautious scenario $5.95, optimistic scenario $9.92. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Corvus Pharmaceuticals Inc stock forecast for 2026?
Our estimate puts fair value at $7.94, about 30% lower versus a price of $11.37 (overvalued). Cautious scenario $5.95, optimistic scenario $9.92. The calculation is refreshed regularly with new filings.
What is the intrinsic value of Corvus Pharmaceuticals Inc (CRVS)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Corvus Pharmaceuticals Inc it is $7.94 per share (as of Nov 11, 2026), against a price of $11.37.
Is Corvus Pharmaceuticals Inc stock overvalued or undervalued in 2026?
As of Nov 11, 2026, CRVS trades above its calculated fair value: price $11.37, fair value $7.94, a gap of about −30% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of CRVS?
No. The price is what the market pays today ($11.37); the fair value is what the company's own numbers justify ($7.94). For Corvus Pharmaceuticals Inc the two are $3.43 per share apart. That gap is exactly why we show both numbers side by side.
How much is Corvus Pharmaceuticals Inc worth?
The market values Corvus Pharmaceuticals Inc at about $1.1B (market capitalisation, as of Nov 11, 2026). Per share that is $11.37; our models calculate a fair value of $7.94 per share.
What do the bullish and bearish scenarios say about CRVS?
Our models span a range for Corvus Pharmaceuticals Inc: cautious scenario $5.95, base $7.94, optimistic $9.92 per share (as of Nov 11, 2026, price $11.37). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Corvus Pharmaceuticals Inc (CRVS)?
Balance-sheet figures for Corvus Pharmaceuticals Inc (as of Nov 11, 2026): return on equity −45.9%. They feed the Quality Score of 57/100, which measures business quality independently of the share price.
How far is CRVS from its 52-week high?
Corvus Pharmaceuticals Inc trades at $11.37, about 55% below its 52-week high of $25.52 and 75% above the low of $6.50 (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of $7.94 is for.
Which stocks are comparable to Corvus Pharmaceuticals Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Corvus Pharmaceuticals Inc stock attractive at the current price?
The data as of Nov 11, 2026: price $11.37, calculated fair value $7.94 (−30%), Quality Score 57/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. Corvus Pharmaceuticals Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Corvus Pharmaceuticals Inc (CRVS)?
The closing price on Nov 10, 2026 was $11.37. Our estimate is $7.94, about 30% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Corvus Pharmaceuticals Inc right now?
The price sits above even our optimistic bull case ($9.92). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (57/100) and above fair value, neither a clear bargain nor a standout compounder.

Key figures of Corvus Pharmaceuticals Inc

How large is the market capitalisation of Corvus Pharmaceuticals Inc (CRVS)?
The market capitalisation of Corvus Pharmaceuticals Inc is $1.1B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Corvus Pharmaceuticals Inc (CRVS)?
Earnings per share at Corvus Pharmaceuticals Inc are $−0.7200. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Corvus Pharmaceuticals Inc (CRVS)?
The return on equity (ROE) of Corvus Pharmaceuticals Inc is −45.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Corvus Pharmaceuticals Inc (CRVS)?
On an EBIT basis the return on assets of Corvus Pharmaceuticals Inc is −47.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How much free cash flow does Corvus Pharmaceuticals Inc (CRVS) generate?
The free cash flow of Corvus Pharmaceuticals Inc is −$33.0M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Corvus Pharmaceuticals Inc (CRVS) hold?
Corvus Pharmaceuticals Inc holds more cash than debt, $3.6M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Corvus Pharmaceuticals Inc in the live analysis

One click puts Corvus Pharmaceuticals Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.